Skip to content

Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.

Bryan L. Roth, Karen Baner, Richard B Westkaemper, Daniel J Siebert, Kenner C Rice, Seanna Steinberg, Paul Ernsberger, Richard B Rothman

Proceedings of the National Academy of Sciences of the United States of America September 3, 2002 DOI: 10.1073/pnas.182234399 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Experimental study Peer reviewed
Intervention Salvinorin A
Topics Salvia divinorum
Keywords Natural compound Plant compound Kappa opioid receptor Kor Receptor activation Human perception Brain function Perceptual disorders Drug discovery Therapeutics New treatments Pharmacology
Citations 782
Key findings Salvinorin A is a potent and selective kappa opioid receptor agonist with no activity at the 5-HT(2A) serotonin receptor, indicating that kappa opioid receptors modulate human perception.

Abstract

Salvia divinorum, whose main active ingredient is the neoclerodane diterpene Salvinorin A, is a hallucinogenic plant in the mint family that has been used in traditional spiritual practices for its psychoactive properties by the Mazatecs of Oaxaca, Mexico. More recently, S. divinorum extracts and Salvinorin A have become more widely used in the U.S. as legal hallucinogens. We discovered that Salvinorin A potently and selectively inhibited (3)H-bremazocine binding to cloned kappa opioid receptors. Salvinorin A had no significant activity against a battery of 50 receptors, transporters, and ion channels and showed a distinctive profile compared with the prototypic hallucinogen lysergic acid diethylamide. Functional studies demonstrated that Salvinorin A is a potent kappa opioid agonist at cloned kappa opioid receptors expressed in human embryonic kidney-293 cells and at native kappa opioid receptors expressed in guinea pig brain. Importantly, Salvinorin A had no actions at the 5-HT(2A) serotonin receptor, the principal molecular target responsible for the actions of classical hallucinogens. Salvinorin A thus represents, to our knowledge, the first naturally occurring nonnitrogenous opioid-receptor subtype-selective agonist. Because Salvinorin A is a psychotomimetic selective for kappa opioid receptors, kappa opioid-selective antagonists may represent novel psychotherapeutic compounds for diseases manifested by perceptual distortions (e.g., schizophrenia, dementia, and bipolar disorders). Additionally, these results suggest that kappa opioid receptors play a prominent role in the modulation of human perception.

Explore topics